MUMBAI: The Maharashtra Food and Drug Administration (FDA) have found 13 drugs which do not match with set standards in the routine random sample testing in the state. In the month of May, Himachal Pradesh and Maharashtra are considered as accountable for major share of the total 13 not-of-standard drugs.
Leading pharma companies such as Galpha Laboratories Limited for Roclav dry syrup 5G/ml (amoxycillin & potassium CL), BRP Pharmaceuticals for oxytocin injection (VET), Twilight Litaka Pharma Limited for Lariclav 625 tablets and Akums Drugs and Pharmaceuticals for amoxycillin and potassium clavulanate oral are figured out in the list of not-of-standard drugs.
From total of 13 drug samples, five were from Himachal Pradesh, four from Maharashtra, and one each from Andhra Pradesh, Bihar, Madhya Pradesh and Uttar Pradesh states. Major products such as India Penicillins Limited (AZIMIC-200 suspension), Perennial Medicare (Optimox CV powder for oral suspension), Theon Pharmaceuticals Ltd (Uniclave dry syrup), Numech Healthcare (prednisolone tablets IP 5mg Pesolen-5) and Twilight Litaka Pharma Limited (Lariclav 625 tablets) having less IP limits.